Utility of a Multi-Marker Panel with Ultrasound for Enhanced Classification of Adnexal Mass

Pre-surgical clinical assessment of an adnexal mass typically relies on transvaginal ultrasound for comprehensive morphological assessment, with further support provided by biomarker measurements and clinical evaluation. Whilst effective for masses that are obviously benign or malignant, a large pro...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2024-06, Vol.16 (11), p.2048
Main Authors: Stephens, Andrew N, Hobbs, Simon J, Kang, Sung-Woog, Oehler, Martin K, Jobling, Tom W, Allman, Richard
Format: Article
Language:English
Subjects:
Adnexitis
Benign
Biological markers
Biomarkers
Classification
Decision making
Diagnosis
Diagnosis, Ultrasonic
Genital cancer
Gynecology
Malignancy
Methods
Oncology
Ovarian cancer
Patients
Preoperative care
Regression analysis
Surgery
Ultrasonic imaging
Ultrasound
Womens health
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pre-surgical clinical assessment of an adnexal mass typically relies on transvaginal ultrasound for comprehensive morphological assessment, with further support provided by biomarker measurements and clinical evaluation. Whilst effective for masses that are obviously benign or malignant, a large proportion of masses remain sonographically indeterminate at surgical referral. As a consequence, post-surgical diagnoses of benign disease can outnumber malignancies up to 9-fold, while less than 50% of cancer cases receive a primary referral to a gynecological oncology specialist. We recently described a blood biomarker signature (multi-marker panel-MMP) that differentiated patients with benign from malignant ovarian disease with high accuracy. In this study, we have examined the use of the MMP, both individually and in combination with transvaginal ultrasound, as an alternative tool to CA-125 for enhanced decision making in the pre-surgical referral process.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16112048